These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10692092)

  • 1. Increased plasma concentrations of TGF-beta1 after hormone replacement therapy.
    Djurovic S; Os I; Hofstad AE; Abdelnoor M; Westheim A; Berg K
    J Intern Med; 2000 Feb; 247(2):279-85. PubMed ID: 10692092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens.
    Taskinen MR; Puolakka J; Pyörälä T; Luotola H; Bjäörn M; Kääriänen J; Lahdenperä S; Ehnholm C
    Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1215-21. PubMed ID: 8857916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women.
    Tilly-Kiesi M; Kahri J; Pyörälä T; Puolakka J; Luotola H; Lappi M; Lahdenperä S; Taskinen MR
    Atherosclerosis; 1997 Mar; 129(2):249-59. PubMed ID: 9105568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteine.
    Os I; Os A; Sandset PM; Bølling S; Seljeflot I; Djurovic S; Westheim A
    Cardiology; 2002; 98(1-2):6-12. PubMed ID: 12373040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum lipoprotein(a) dynamics before/after menopause and long-term effects of hormone replacement therapy on lipoprotein(a) levels in middle-aged and older Japanese women.
    Ushioda M; Makita K; Takamatsu K; Horiguchi F; Aoki D
    Horm Metab Res; 2006 Sep; 38(9):581-6. PubMed ID: 16981140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the type of hormone replacement therapy affect lipoprotein (a), homocysteine, and C-reactive protein levels in postmenopausal women?
    Bukowska H; Stanosz S; Zochowska E; Millo B; Sieja K; Chełstowski K; Naruszewicz M
    Metabolism; 2005 Jan; 54(1):72-8. PubMed ID: 15562383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status.
    Gilabert J; Estellés A; Cano A; España F; Barrachina R; Grancha S; Aznar J; Tortajada M
    Am J Obstet Gynecol; 1995 Dec; 173(6):1849-54. PubMed ID: 8610774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions.
    Espeland MA; Marcovina SM; Miller V; Wood PD; Wasilauskas C; Sherwin R; Schrott H; Bush TL
    Circulation; 1998 Mar; 97(10):979-86. PubMed ID: 9529266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease.
    Sbarouni E; Kyriakides ZS; Kremastinos DTh
    J Am Coll Cardiol; 1998 Nov; 32(5):1244-50. PubMed ID: 9809932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating transforming growth factor-beta1, lipoprotein(a) and cellular adhesion molecules in angiographically assessed coronary artery disease.
    Bogavac-Stanojevic N; Djurovic S; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Kalimanovska-Ostric D
    Clin Chem Lab Med; 2003 Jul; 41(7):893-8. PubMed ID: 12940514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone.
    van der Mooren MJ; Demacker PN; Thomas CM; Borm GF; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1993 Dec; 52(2):117-23. PubMed ID: 8157140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis.
    Anagnostis P; Galanis P; Chatzistergiou V; Stevenson JC; Godsland IF; Lambrinoudaki I; Theodorou M; Goulis DG
    Maturitas; 2017 May; 99():27-36. PubMed ID: 28364865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause.
    Shlipak MG; Simon JA; Vittinghoff E; Lin F; Barrett-Connor E; Knopp RH; Levy RI; Hulley SB
    JAMA; 2000 Apr; 283(14):1845-52. PubMed ID: 10770146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.
    Eilertsen AL; Høibraaten E; Os I; Andersen TO; Sandvik L; Sandset PM
    Maturitas; 2005 Oct; 52(2):111-8. PubMed ID: 16186073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin sensitivity in women with coronary heart disease during hormone replacement therapy.
    Os I; Os A; Abdelnoor M; Larsen A; Birkeland K; Westheim A
    J Womens Health (Larchmt); 2005 Mar; 14(2):137-45. PubMed ID: 15775731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women.
    Mc Manus J; Mc Eneny J; Thompson W; Young IS
    Atherosclerosis; 1997 Nov; 135(1):73-81. PubMed ID: 9395275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of oral and transdermal hormone replacement therapy on lipid profile and Lp(a) level in menopausal women with hypercholesterolemia.
    Perrone G; Stefanutti C; Galoppi P; Anelli G; Capri O; Lucani G; Vivenzio A; Mazzarella B; Zichella L
    Int J Fertil Menopausal Stud; 1996; 41(6):509-15. PubMed ID: 9010744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycaemic control and plasma lipoproteins in menopausal women with Type 2 diabetes treated with oral and transdermal combined hormone replacement therapy.
    Darko DA; Dornhorst A; Kennedy G; Mandeno RC; Seed M
    Diabetes Res Clin Pract; 2001 Dec; 54(3):157-64. PubMed ID: 11689270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study.
    Stojanovic ND; Kwong P; Byrne DJ; Arnold A; Jagroop IA; Nair D; Press M; Hurel S; Mikhailidis DP; Prelevic GM
    Angiology; 2003; 54(4):391-9. PubMed ID: 12934758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-oral HRT and lipoprotein metabolism. Which progestin-- dydrogesterone or medroxyprogesterone acetate?
    Bhathena RK; Ganatra AM; Pinto R; Anklesaria BS
    Int J Gynaecol Obstet; 2000 May; 69(2):177-80. PubMed ID: 10802094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.